Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-6 R alpha

IL-6 R alpha

Brief Information

Name:Interleukin-6 receptor alpha subunit
Target Synonym:IL6RA,IL6RQ,IL6Q,Interleukin-6 Receptor alpha Subunit,sIL6R,gp80,IL-6R subunit alpha,Membrane glycoprotein 80,IL6R,Interleukin 6 Receptor,IL-6 Receptor Subunit Alpha,CD126 Antigen,IL-6R 1,IL-6RA,Interleukin-6 Receptor Subunit Alpha,IL-6R-Alpha,IL-6R-1,CD126
Number of Launched Drugs:6
Number of Drugs in Clinical Trials:13
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

ILR-H5259-BLI
 IL-6 R alpha BLI

Loaded Human IL-6 R alpha, Fc Tag (Cat. No. ILR-H5259) on Protein A Biosensor, can bind Human IL-6, premium grade (Cat. No. IL6-H4218) with an affinity constant of 35.9 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

CD6-H82E8-BLI
 IL-6 R alpha BLI

Loaded Biotinylated Human IL-6 R alpha, Avitag,His Tag (Cat. No. CD6-H82E8) on SA Biosensor, can bind Human IL-6, premium grade (Cat. No. IL6-H4218) with an affinity constant of 73.1 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

IL6R,CD126,IL-6R-1,IL-6RA,IL6RA,IL-6R-alpha,IL6RQ,gp80

Background

Interleukin 6 receptor (IL6R) is also known as CD126 (Cluster of Differentiation 126) , is a potent pleiotropic cytokine that regulates cell growth and differentiation of various tissues, and is known particularly for its role in the immune response and acute phase reactions. IL6R is a protein complex consisting of a IL-6 receptor subunit (IL6R) and interleukin 6 signal transducer Glycoprotein 130. IL6R also denotes the human gene encoding this subunit. Alternatively spliced transcript variants encoding distinct isoforms have been reported. IL6R subunit also shared by many other cytokines. The soluble form of IL6R arises from proteolytic cleavage of membrane-bound IL6Rα, and acts agonistically by making the IL6 ligand accessible to the signal transducer gp130. Dysregulated production of IL6 and IL6R are implicated in the pathogenesis of several inflammatory diseases and malignancies such as multiple myeloma, rheumatoid arthritis, or osteoporosis, and it has been reported that a humanized anti-IL6R monoclonal antibody is a promising agent applicable to the therapeutic approach for IL6 driven diseases. Interleukin-6 receptor has been shown to interact with Interleukin 6 and Ciliary neurotrophic factor.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tocilizumab biosimilar (Livzon Group) LZM-008 Approved Livzon Pharmaceutical Group Inc 安维泰 Mainland China Arthritis, Rheumatoid Livzon Mabpharm Inc 2023-01-18 Arthritis, Rheumatoid Details
Tocilizumab biosimilar (Bio-Thera Solutions) BAT-1806; BIIB-800 Approved Bio-Thera Solutions Ltd 施瑞立, TOFIDENCE Mainland China Arthritis, Rheumatoid; Arthritis, Juvenile; Cytokine Release Syndrome Bio-Thera Solutions Ltd 2023-01-16 Cytokine Release Syndrome; Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid; Arthritis, Juvenile Details
Satralizumab RG-6168; SA-237 Approved Chugai Pharmaceutical Co Ltd Enspryng, エンスプリング Japan Neuromyelitis Optica Chugai Pharmaceutical Co Ltd 2020-06-29 Myasthenia Gravis; Brain Ischemia; Graves Ophthalmopathy; Neuromyelitis Optica; Pulmonary Arterial Hypertension; Encephalitis; Subarachnoid Hemorrhage; Anti-N-Methyl-D-Aspartate Receptor Encephalitis Details
Tocilizumab biosimilar (Fresenius kabi) MSB-11456 Approved Merck Serono EU Cytokine Release Syndrome; Arthritis, Rheumatoid; Giant Cell Arteritis Fresenius Kabi Deutschland Gmbh 2023-09-15 Cytokine Release Syndrome; Giant Cell Arteritis; Arthritis, Rheumatoid Details
Tocilizumab MRA; HPM-1; MRA-SC; R-1569; rhPM-1; RG-1569; RO-48775533 Approved Chugai Pharmaceutical Co Ltd Actemra/RoActemra, 雅美罗, Actemra, RoActemra Japan Arthritis, Juvenile; Arthritis, Rheumatoid; Giant Cell Arteritis; Takayasu Arteritis; Cytokine Release Syndrome; Multicentric Castleman's Disease (MCD) null 2005-04-11 Uveitis; Respiratory Distress Syndrome, Adult; systemic sclerosis-associated interstitial lung disease; Lupus Erythematosus, Systemic; Coronavirus Infections; Pulmonary Arterial Hypertension; Takayasu Arteritis; Coronary Disease; Multicentric Castleman's Disease (MCD); Breast Neoplasms; Coronaviridae Infections; Fever; Pleural Effusion, Malignant; Pulmonary Disease, Chronic Obstructive; Polymyalgia Rheumatica; Osteoarthritis; Inflammation; Uveitis, Posterior; Lymphoma; Rejection in heart transplantation; Non-ST Elevated Myocardial Infarction; Anemia, Sickle Cell; Kidney Failure, Chronic; Diabetes Mellitus; Behcet Syndrome; Amyotrophic Lateral Sclerosis; Panuveitis; Carcinoma, Hepatocellular; Myocardial Infarction; Cytokine Release Syndrome; Non-radiographic axial spondyloarthritis; Craniopharyngioma; Motor Neuron Disease; Polymyositis; Diabetes Mellitus, Type 1; Hematologic Neoplasms; Solid tumours; HIV Infections; Polyarticular Juvenile Idiopathic Arthritis; Dermatomyositis; Giant Cell Arteritis; Schnitzler Details
Sarilumab REGN-88; SAR-153191 Approved Sanofi, Regeneron Pharmaceuticals Inc Kevzara United States Arthritis, Rheumatoid Sanofi-Synthelabo 2017-05-22 Non-radiographic axial spondyloarthritis; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Mastocytosis, Systemic; Sarcoidosis; Polymyalgia Rheumatica; Arthritis, Juvenile; Severe Acute Respiratory Syndrome; Uveitis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
VDJ-001 Phase 2 Clinical Beijing Vdjbio Co Ltd Arthritis, Rheumatoid; Multicentric Castleman's Disease (MCD) Details
Tocilizumab Biosimilar (qyuns) QX-003-S Phase 1 Clinical Qyuns Therapeutics Co Ltd Arthritis, Rheumatoid Details
Tocilizumab Biosimilar (Destiny) IA-001; IA001 Phase 1 Clinical Shanghai Destiny Biotech Co Ltd Polyarticular Juvenile Idiopathic Arthritis; Arthritis, Rheumatoid Details
Tocilizumab biosimilar (Celltrion) CT-P47; CT-P-47 Phase 3 Clinical Celltrion Inc Arthritis, Rheumatoid Details
Tocilizumab biosimilar (AryoGen Pharmed) Phase 3 Clinical Aryogen Biopharma Arthritis, Rheumatoid Details
Recombinant humanized anti-IL-6R antibody (Hisun Pharma) HS-628 Phase 3 Clinical Zhejiang Hisun Pharmaceutical Co Ltd Arthritis, Rheumatoid; Arthritis Details
CMAB806 CMAB-806 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Arthritis, Rheumatoid; Arthritis Details
Levilimab BCD-089 Phase 3 Clinical Biocad Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19) Details
Atexakin alfa SON-080; r-IL-6 Phase 2 Clinical Merck Serono, Weizmann Institute Of Science Peripheral Nervous System Diseases; Diabetic Neuropathies Details
Olamkicept FE-999301; CR-5/18; TJ-301; FE-301 Phase 2 Clinical Conaris Research Institute Colitis, Ulcerative Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message